

Structure–activity relationship of phosmidosine: importance of the 7,8-dihydro-8-oxoadenosine residue for antitumor activity

Mitsuo Sekine,^{a,b,*} Kazuhisa Okada,^a Kohji Seio,^{b,c} Hideaki Kakeya,^d
Hiroyuki Osada^d and Takuma Sasaki^c

^aDepartment of Life Science, Tokyo Institute of Technology, Nagatsuda, Midoriku, Yokohama 226-8501, Japan

^bFrontier Collaborative Research Institute, Tokyo Institute of Technology, Nagatsuda, Midoriku, Yokohama 226-8501, Japan

^cCREST, JST (Japan Science and Technology Corporation), Nagatsuda, Midoriku, Yokohama 226-8501, Japan

^dAntibiotics Laboratory, The Institute of Physical and Chemical Research (RIKEN),

2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan

^eCancer Research Institute, Kanazawa University, Takara-machi, Kanazawa 920-8640, Japan

Received 17 June 2004; revised 8 July 2004; accepted 8 July 2004

Available online 7 August 2004

Abstract—To study the structure–activity relationship of phosmidosine, a variety of phosmidosine derivatives **9a–g** were synthesized by condensation of *N*-diisopropyl *N'*-(*N*-tritylpropyl)phosphorodiamidite **6** with appropriately protected nucleoside derivatives **7a–g**. As the result, replacement of the 7,8-dihydro-8-oxoadenosine base by adenine and 6-*N*-acetyladenine did not affect the antitumor activity. However, phosmidosine derivatives containing uracil, cytosine, and guanine in place of the 7,8-dihydro-8-oxoadenosine base did not show significant activity. A plausible explanation for the selective expression of phosmidosine compared with that of phosmidosine analogs having other amino acids in place of proline is also discussed. These results suggest that phosmidosine serves as an inhibitor of prolyl adenosine 5'-phosphate (prolyl-AMP) to inhibit the peptide synthesis in cancer-related cells.

© 2004 Elsevier Ltd. All rights reserved.

1. Introduction

Phosmidosine (**1**) was discovered as an antifungal antibiotic in 1991.¹ The structure of **1** was determined based on mass spectroscopy in 1993.² Later, this naturally occurring product has proved to have biological activity capable of morphological reversion of src^{ts}NKR cells.³ As an intriguing characteristic of this molecule, it serves as a G1 arrest anticancer drug in a cell cycle.³ Phosmidosine regulates hyperphosphorylation of RB proteins by inhibition of Cyclin D1 so that RB proteins remain in inactive forms keeping binding to EF2.⁴ This inhibition takes place at the G1 phase. However, phosmidosine itself is somewhat unstable under physiological conditions.² Phosmidosine B (**2**) is one degradation product

of phosmidosine.¹ This demethylated species has still 1/20 of the morphological reversion activity of phosmidosine.¹ In 2000, we first synthesized phosmidosine B and found that this compound has significant antitumor activities against various cancer-related cell lines.⁵ Recently, we also succeeded in synthesizing phosmidosine.⁶ However, it turned out that this *O*-methyl ester tends to decompose during the isolation procedure so that the isolation yield is not so high (27%). This is due to intermolecular and intramolecular transfer reactions of the methyl group on the phosphoramidate linkage.¹ Therefore, we have quite recently synthesized a variety of more stable derivatives of phosmidosine that can maintain the antitumor activity.⁷ Among them, the *O*-ethyl ester derivative (**3**) proved to be sufficiently stable and exhibited sufficient antitumor activities against KB and L1210 cell lines.⁷ Furthermore, it was found that both the prolyl and 7,8-dihydro-8-oxoadenosyl residues are important for the biological activity. The substitution of an acetyl group or other aminoacyl groups for the prolyl group resulted in considerable loss of the activity.

Keywords: Phosmidosine; Structure–activity relationship; 8-Oxoadenosine; Antitumor activity; Aminoacyl adenylate analog.

* Corresponding author. Tel.: +81-45-924-5706; fax: +81-45-924-5772; e-mail: msekine@bio.titech.ac.jp




Figure 1. Various derivative of phosmidosine and prolyl-AMP.

The prolyl group is an essential element. The replacement of 7,8-dihydro-8-oxoadenosine with a simple ethyl group led to drastic loss of the activity. With an increase of the alkyl group in place of the methyl group on the phosphoramidate linkage, the activity decreased slightly.

In connection with our recent studies, we previously reported the synthesis^{8,9} of several adenosine 5'-[*N*-(aminoacyl)phosphoramidate] derivatives [aminoacylamido-AMPs] containing an analog (**5**) of prolyl adenylate (**4**: prolyl-AMP) that would be useful as co-factors for X-ray analysis of aminoacyl-tRNA synthetase complexes (Fig. 1). It was also found that the synthetic aminoacylamido AMPs have weak antitumor activities against various cell lines.

Phosmidosine has structural elements close to those of prolyl-AMP (**4**), which serves as a carrier of a proline amino acid to the 3'-terminal site of tRNA^{Pro} via a tri-particle complex with a prolyl-tRNA synthetase. Therefore, it is strongly suggested that phosmidosine might

show significant antitumor activity in rapidly growing cancer cells as an inhibitor of the peptide synthesis.


To clarify this possibility, the structure–activity relationship of phosmidosine is of great importance. Particularly, it should be clarified if the 7,8-dihydro-8-oxoadenosine component can be replaced by other elements such as the deoxy counterpart, the adenosine, and other ribonucleosides without loss of the activity.

In this paper, we report the synthesis of various derivatives of the phosmidosine *O*-ethyl ester by replacement of the adenosine moiety by other nucleoside derivatives and also their antitumor activities.


2. Results and discussion

To study the structure–activity relationship of phosmidosine, we synthesized a series of phosmidosine derivatives (**9a–g**). Phosmidosine has a unique structure of the 7,8-dihydro-8-oxoadenine base. Therefore, to see if the 7,8-dihydro-8-oxoadenine moiety is essential for the antitumor activity, we synthesized the *O*-ethyl ester derivative (**9a**) of prolylamido AMP replaced by adenosine in place of 7,8-dihydro-8-oxoadenosine. Moreover, to check the necessity of the ribose residue, the 2'-deoxyadenosine and 2'-deoxy-7,8-dihydro-8-oxoadenosine derivatives **9b** and **9c** were also prepared. In addition, we synthesized 6-*N*-acetylphosmidosine derivative **9d** to check if the 6-amino group of phosmidosine can be modified without loss of the activity. We also synthesized several compounds **9e–g** having other nucleobases in place of 7,8-dihydro-8-oxoadenine. The synthesis of these compounds is outlined in Scheme 1.

For the construction of the *N*-prolylphosphoramidate linkage, ethyl *N*-diisopropyl-*N'*-[*N*-tritylprolyl]phosphorodiamidite (**6**)⁷ was activated by the action of 5-mercapto-1-methyl-1*H*-tetrazole (MMT)^{10,11} to react with



Scheme 1. Synthesis of phosmidosine analogs by MMT-catalyzed phosphoramidite coupling reactions.



Scheme 2. Synthesis of key intermediates required for the synthesis of phosmidosine analogs.

appropriately protected nucleoside derivatives (**7a–g**). The oxidation of the resulting trivalent phosphorus intermediates was carried out by use of *t*-BuOOH.¹² The starting materials **7a**,¹³ **7b**,¹⁴ and **7e**¹³ were obtained by the literature method. 3'-*O*-TBDMS-7,8-dihydro-8-oxodeoxyadenosine (**7c**) was synthesized from 8-bromodeoxyadenosine via 8-oxodeoxyadenosine (**10**), as shown in **Scheme 2**. Compound **7d** was also synthesized by a two-step reaction of 6-*N*-acetyl-8-oxodeoxyadenosine (**11**).

Table 1. Condensation of **6** with **7a–g** to give the *N*-prolylphosphoramidate derivatives **8a–g**

Compd (7/6)	MMT/6	Product	Condensation time (min)	Oxidation time (min)	Yield (%)
7a 2.0	1.26	8a	60	10	60
7b 2.0	1.26	8b	10	10	58
7c 1.5	1.67	8c	60	10	43
7d 2.0	1.25	8d	10	10	55
7e 2.0	1.25	8e	10	10	89
7f 2.0	1.25	8f	10	10	91
7g 2.0	1.25	8g	10	10	72

For the synthesis of the cytidine and guanosine derivatives **9f** and **9g**, 4-*N*-DMTr-2',3'-*O*-bis(*tert*-butyldimethylsilyl)cytidine **7f** and *N*-DMTr-2',3'-*O*-bis(*tert*-butyldimethylsilyl)guanosine **7g** were synthesized, as shown in **Scheme 2**. Compound **7f** was synthesized in 43% yield from cytidine (**12**) via a five-step procedure without isolation of each intermediate. Compound **7g** was prepared in 63% yield from 2',3',5'-*O*-tris(*tert*-butyldimethylsilyl)guanosine (**13**).¹³

The results of the coupling reactions between **6** and **7a–g** are shown in **Table 1**. Desilylation followed by detritylation of **8a–g** gave the final products **9a–g** in satisfactory yields except for **9a** and **9b**. The details of the deprotection are summarized in **Table 2**. Compounds **9a** and **9f** were isolated as the trifluoroacetate salts but **9b–e** and **9g** were obtained as *N*-unprotonated species. The presence of excess TBAF, which was used for desilylation, might inhibit the salt formation of **9b–e** and **9g**.

The antitumor activities of these compounds obtained by the MTT assay¹⁵ are shown in **Table 3**. For the assay, a set of diastereoisomers were used, since in the previous study each of the diastereoisomers of the *O*-alkylated phosmidosine derivative showed similar biological activities in anticancer tests and morphological reversion activity.⁷

The IC₅₀ values of **Table 3** show that the compounds tested exhibited similar antitumor activities against KB and L1210 cell lines except for the result of the deoxy counterpart **9b** in the L1210 cell line. Therefore, the presence of the 2'-hydroxyl group or 8-oxo function is not so important for the biological expression. It turned out that the *N*-acetyl derivative **9d** also showed similar antitumor activity to that of **9a**. This result implies that an *N*-acyl modification is useful for functionalization of phosmidosine to search for biomolecules, which interact

Table 2. Deprotection of fully protected phosmidosine derivatives **8a–g**

Compd	Desilylation		Detritylation		Product	Yield of 9
	TBSF (equiv)	Time (h)	Conditions	Time		
8a			80% HCOOH	42 h	9a	19
8b	TBAF 3.9	6	1% TFA H ₂ O–CH ₃ CN (1:1, v/v)	15 min	9b	72
8c	TBAF 6.0	4	1% TFA H ₂ O–CH ₃ CN (1:1, v/v)	15 min	9c	58
8d	TBAF 10.0	4	1% TFA H ₂ O–CH ₃ CN (1:1, v/v)	15 min	9d	29
8e	TBAF 7.9	2	1% TFA H ₂ O–CH ₃ CN (1:1, v/v)	15 min	9e	91
8f	TBAF 8.1	1	4% TFA H ₂ O–CH ₃ CN (1:1, v/v)	3 + 12 h	9f	60
8g	TBAF 8.2	3	4% TFA H ₂ O–CH ₃ CN (1:1, v/v)	1 h	9g	69

Table 3. Antitumor activity of phosmidosine analogs

Compd	IC ₅₀ (μM)	
	KB	L1210
Phosmidosine-Et 3	3.44	3.62
A-phosmidosine-Et 9a	5.12	3.62
dA-phosmidosine-Et 9b	3.85	21.6
8-Oxo-dA-phosmidosine-Et 9c	3.23	5.68
N-Ac-8-oxo-A-phosmidosine-Et 9d	2.89	4.10
U-phosmidosine-Et 9e	>170	>170
C-phosmidosine-Et 9f	>170	>170
G-phosmidosine-Et 9g	>200	>200

with phosmidosine. The most plausible binding molecule might be a tRNA synthetase. From the results of the MTT assay obtained above, it is strongly suggested that prolyl-tRNA synthetase binds to phosmidosine like aminoacyl AMPs.

When the U-, G-, and C-phosmidosine-Et derivatives **7e–g** were tested, no significant antitumor activities were detected, as shown in Table 3. These results suggest that the replacement of the 7,8-dihydro-8-oxoadenine base with other bases such as uracil, guanine, and cytosine resulted in loss of the activity. This is reasonable if phosmidosine recognizes aminoacyl-tRNA synthetase, which would allow binding with the adenine base and its close analogs and thereby serves as an inhibitor.

3. Conclusion

In conclusion, it turned out that the 7,8-dihydro-8-oxoadenine is exchangeable to an adenine moiety and the deoxy counterpart did not affect the biological activity in KB cells but decreased it four times in the L1210 cell line. At any rate, the base part is essentially more important than the ribose moiety. Essentially, at least the adenine skeleton must be required. Since it is clear that the adenine or 7,8-dihydro-8-oxoadenine base is essential for antitumor activity, the possibility that phosmidosine actually interacts with an aminoacyl-tRNA synthetase increases. On the other hand, we have also reported that replacement of the prolyl group by other amino acid residues resulted in poorer antitumor activity.⁷ If phosmidosine serves as an inhibitor in the peptide synthesis, these derivatives having other amino acids should express similar activities. Future studies are required to address this point. However, we also noticed the *O*-methyl phosmidosine derivatives having other amino acids tend to decompose even under neutral conditions on storage and were less stable than phosmidosine. This is because the other amino acids have primary amino groups so that intramolecular *N–N* rearrangement easily occurs compared with phosmidosine that has a secondary amino group on the five-membered ring not accessible to such cyclization.⁷ Based on these discussions, it is likely that such modified phosmidosine derivatives cannot exist in cells for sufficient time to interact with the corresponding aminoacyl-tRNA synthetases so that only phosmidosine, which has a longer lifetime, survives in

cells and shows antitumor and morphological reversion activities in cancer cells.

Apart from our studies, 5'-*O*-[*N*-aminoacylsulfamoyl]-adenosine and its analogs have been synthesized^{16–18} in connection with the structure–activity relationship of ascamysine,¹⁹ which has a 2-chloroadenosine moiety. These studies clearly indicate that the aminoacyl group recognizes the corresponding aminoacyl-tRNA synthetases. In these cases, such restricted recognition takes place since the sulfonamide ester linkage is chemically stable and no *N–N* rearrangement of the sulfonyl group occurs.

At the next stage of our study, extensive study should be done to isolate biomolecules, which interact with phosmidosine by use of suitably modified phosmidosine derivative having a biotin residue at the 6-*N*-acyl chain. Further study is now under way in this direction.

4. Experimental section

4.1. General remarks

¹H, ¹³C, and ³¹P NMR spectra were obtained at 270, 68, and 109 MHz, respectively. The chemical shifts were measured from tetramethylsilane (0 ppm) or DMSO-*d*₆ (2.49 ppm) for ¹H NMR, CDCl₃ (77.0 ppm), DMSO-*d*₆ (39.7 ppm) or DMF-*d*₇ (2.74 ppm) for ¹³C NMR, and 85% phosphoric acid (0 ppm) for ³¹P NMR. Column chromatography was performed with silica gel C-200. Reverse-phase column chromatography was performed by use of 37–55 μm C18 (125 Å) particles, which were set up in a glass column of a medium pressure preparative HPLC system. Elution was performed with the following solvent systems I–II for 500 min at a flow rate of 2.0 mL/min. Solvent system I: water–acetonitrile (100–0 to 70:70, v/v); solvent system II: water–MeOH–trifluoroacetic acid (93:7:0.1, v/v/v). Reverse-phase HPLC was performed using C18 columns (3.9×150 mm and 7.8×300 mm, respectively) with a linear gradient of 0–15% CH₃CN/H₂O containing 0.1 M NH₄OAc (pH 7.0) at 50 °C at a flow rate of 1.0 and 3.0 mL/min, respectively, for 30 min. Mass spectra were measured by use of an ESI-mass spectrophotometer and a MALDI-TOF mass spectrophotometer. UV spectra were measured by a U-2000 spectrophotometer. TLC was performed with silica gel 60 (F₂₅₄) plates. In vitro analysis of the antitumor activity in various cancer cell lines was carried out by the literature method reported by Carmichael et al.¹⁵ and us.⁷ The morphological reversion activity test was conducted according to the literature method.³ Compounds **6** were synthesized according to the previous method reported.⁷ Compounds **7a** and **7e–g** were synthesized according to the literature method.¹⁴ Compound **7b** was synthesized by the Robins method.¹⁴ Compound **11** was synthesized by our previous method.⁶

4.1.1. 3'-*O*-*tert*-Butyldimethylsilyl-7,8-dihydro-8-oxodeoxyadenosine (7c). Compound **10**²⁰ (802 mg, 3.0 mmol) was rendered anhydrous by coevaporation three times

with dry pyridine and finally dissolved in dry DMF (3 mL). To the solution were added *tert*-butyldimethylsilyl chloride (1.09 g, 7.2 mmol) and imidazole (980 mg, 14.4 mmol). After being stirred under argon atmosphere at room temperature for 3 h, the mixture was diluted with AcOEt. The solution was washed three times with 5% NaHCO₃, and the organic layer was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was dissolved in acetic acid–THF–water (3:1:1, v/v/v, 30 mL). After being stirred at 80 °C for 5 h, the mixture was diluted CHCl₃. The CHCl₃ solution was washed successively twice with water and with 5% NaHCO₃. The organic layer was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with CHCl₃–MeOH (98:2, v/v) to give **7c** (360 mg, 31%): ¹H NMR (270 MHz, DMSO-*d*₆) δ 0.00 (6H, s), 0.79 (9H, s), 1.86–1.94 (1H, m, *J*_{2'-Ha,2'-Hb} = 6.3 Hz), 2.92–3.02 (1H, m), 3.32–3.38 (1H, m, *J*_{5'-Ha,5'-Hb} = 6.9 Hz), 3.48–3.53 (1H, m), 3.68–3.69 (1H, m), 4.50 (1H, m), 4.98–5.02 (1H, m, *J*_{5'-OH,5'-Ha} = *J*_{5'-OH,5'-Hb} = 4.6 Hz), 6.01 (1H, t, *J*_{1',2'-Ha} = 6.6 Hz, *J*_{1',2'-Hb} = 7.3 Hz), 6.44 (2H, br s), 7.91 (1H, s), 10.24 (1H, br s); ¹³C NMR (DMSO-*d*₆) δ –4.75, –4.71, 17.78, 25.75, 36.20, 61.94, 73.05, 81.16, 87.39, 103.37, 146.22, 146.96, 150.41, 151.03. ESI-mass *m/z* calcd for C₁₆H₂₈N₅O₄Si 382.1911; observed [*M* + *H*] 382.1944.

4.1.2. 6-*N*-Acetyl-2',3'-*O*-di-*tert*-butyldimethylsilyl-7,8-dihydro-8-oxoadenosine (7d). Compound **11**⁶ (1.11 g, 3.42 mmol) was rendered anhydrous by coevaporation three times with dry pyridine and finally dissolved in dry pyridine (34 mL). To the solution was added 4,4'-dimethoxytrityl chloride (1.27 g, 3.76 mmol). After being stirred under argon atmosphere at room temperature for 3 h, the mixture was quenched by addition of MeOH (25 mL). The mixture was partitioned between CHCl₃ and 5% NaHCO₃. The organic layer was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was coevaporated three times with dry pyridine and finally dissolved in dry DMF (34 mL). To the mixture were added *tert*-butyldimethylsilyl chloride (1.13 g, 7.52 mmol) and imidazole (1.02 g, 15.0 mmol). After being stirred at room temperature for 12 h, the mixture was diluted CHCl₃. The CHCl₃ solution was washed three times with 5% NaHCO₃. The organic layer was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was dissolved in a 2% solution of trifluoroacetic acid in CHCl₃ (34 mL). After being stirred at room temperature for 30 min, the mixture was diluted CHCl₃. The CHCl₃ solution was washed three times with 5% NaHCO₃. The organic layer was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with CHCl₃–MeOH (99:1, v/v) to give **7d** (1.10 g, 58%): ¹H NMR (270 MHz, DMSO-*d*₆) δ –0.33 (3H, s), –0.13 (3H, s, CH₃ of TBDMS), 0.06 (3H, s), 0.07 (3H, s), 0.69 (9H, s), 0.86 (9H, s), 2.08 (3H, s), 3.39–3.48 (1H, m, *J*_{5'-Ha,5'-Hb} = 6.6 Hz), 3.58–3.69 (1H, m), 3.84 (1H, m), 4.33–4.35 (1H, m), 4.89–4.93 (1H, m), 5.22–5.15 (1H, t, *J*_{5'-OH,5'-Ha} = 4.9 Hz), 5.75 (1H, d,

*J*_{1',2'} = 6.6 Hz), 8.38 (1H, s), 10.32 (1H, br s), 10.82 (1H, br s); ¹³C NMR (DMSO-*d*₆) δ –5.3, –4.7, –4.63, –4.59, 17.6, 17.8, 23.2, 25.5, 25.8, 61.4, 70.5, 72.6, 84.9, 85.9, 110.9, 138.2, 149.5, 150.0, 150.9, 169.2. ESI-mass *m/z* calcd for C₂₄H₄₄N₅O₆Si₂ 554.2830; observed [*M* + *H*] 554.2742.

4.1.3. 2',3'-*O*-Di-*tert*-butyldimethylsilyl-4-*N*-(4,4'-dimethoxytrityl)cytidine (7f). Cytidine (**12**) (973 mg, 4.0 mmol) was rendered anhydrous by coevaporation three times with dry pyridine and finally dissolved in dry DMF (8 mL). To the mixture were added *tert*-butyldimethylsilyl chloride (2.17 g, 14.4 mmol) and imidazole (1.96 g, 28.8 mmol). After being stirred at room temperature for 10 h, the mixture was diluted CHCl₃. The CHCl₃ solution was washed three times with 5% NaHCO₃. The organic layer was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was dissolved in acetic acid–THF–water (3:1:1, v/v/v) (40 mL). After being stirred at 80 °C for 14 h, the mixture was diluted CHCl₃. The CHCl₃ solution was washed twice with water and three times with 5% NaHCO₃. The organic layer was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was rendered anhydrous by coevaporation three times with dry pyridine and finally dissolved in dry pyridine (40 mL). To the solution was added trimethylsilyl chloride (1.01 mL, 8.0 mmol). After the mixture was stirred under argon atmosphere at room temperature for 30 min, 4,4'-dimethoxytrityl chloride (1.49 g, 4.4 mmol) was added. After being stirred at room temperature for 3 h, the mixture was quenched by addition of 28% aqueous ammonia (10 mL). The mixture was stirred at room temperature for an additional 30 min. The mixture was evaporated under reduced pressure and diluted CHCl₃. The CHCl₃ solution was washed three times with 5% NaHCO₃. The organic layer was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with hexane–AcOEt–pyridine (70:30:1–60:40:1, v/v/v) to give **7f** (1.32 g, 43%): ¹H NMR (270 MHz, DMSO-*d*₆) δ –0.21 (3H, s), –0.11 (3H, s), 0.00 (3H, s), 0.01 (3H, s), 0.74 (9H, s), 0.81 (9H, s), 3.47–3.54 (2H, m, 5'-H), 3.66 (6H, s), 3.76–3.77 (1H, m), 3.99–4.02 (1H, m), 4.10–4.12 (1H, m), 5.11 (1H, m), 5.61 (1H, d, *J*_{1',2'} = 5.6 Hz), 6.19 (1H, d, *J*_{5,6} = 7.3 Hz), 6.75 (4H, d, *J*_{meta,ortho} = 8.6 Hz), 7.06–7.17 (9H, m), 7.70 (1H, d, 6-H), 8.31 (1H, br s); ¹³C NMR (DMSO-*d*₆) δ –5.0, –4.82, –4.77, –4.6, 17.7, 17.79, 17.84, 25.68, 25.74, 54.9, 60.6, 69.3, 72.1, 74.4, 79.1, 85.3, 88.1, 96.3, 112.5, 113.2, 123.7, 125.9, 127.2, 128.3, 129.7, 135.9, 136.7, 140.0, 144.8, 149.4, 154.0, 157.2, 163.0; ESI-mass *m/z* calcd for C₄₂H₆₀N₃O₇Si₂ 774.3970; observed [*M* + *H*] 774.3973.

4.1.4. 2',3'-*O*-Di-*tert*-butyldimethylsilyl-2-*N*-(4,4'-dimethoxytrityl)guanosine (7g). Compound **13**¹³ (939 mg, 1.5 mmol) was dissolved in acetic acid–THF–water (3:1:1, v/v/v) (15 mL). After being stirred at 80 °C for 10 h, the mixture was diluted CHCl₃. The CHCl₃ solution was washed twice with water and with 5% NaHCO₃. The organic layer was collected, dried over

Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was rendered anhydrous by coevaporation three times with dry pyridine and finally dissolved in dry pyridine (15 mL). To the solution was added trimethylsilyl chloride (123 μ L, 2.0 mmol). After the mixture was stirred under argon atmosphere at room temperature for 1 h, 4,4'-dimethoxytrityl chloride (508 mg, 1.5 mmol) was added. After being stirred at room temperature for 4 h, the mixture was quenched by addition of 28% aqueous ammonia (6 mL). The mixture was stirred at room temperature for an additional 2 h. The mixture was evaporated under reduced pressure and diluted CHCl₃. The CHCl₃ solution was washed three times with 5% NaHCO₃. The organic layer was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with hexane–AcOEt–pyridine (70:30:1–60:40:1, v/v/v) to give **7g** (767 mg, 63%): ¹H NMR (270 MHz, DMSO-*d*₆) δ –0.34 (3H, s, CH₃ of TBDMS), –0.16 (3H, s), 0.03 (3H, s, CH₃ of TBDMS), 0.08 (3H, s), 0.70 (9H, s), 0.85 (9H, s), 3.43 (2H, m), 3.68–3.73 (7H, m), 4.08–4.10 (1H, m), 4.42–4.45 (1H, m), 5.02 (1H, m), 5.26–5.29 (1H, d, $J_{1',2'} = 7.9$ Hz), 6.78 (4H, d, $J_{ortho,meta} = 8.2$ Hz), 7.16–7.25 (9H, m), 7.55 (1H, br s, 2-NH), 7.88 (1H, s), 10.59 (1H, br s); ¹³C NMR (DMSO-*d*₆) δ –4.2, –3.9, –3.80, –3.76, 18.5, 18.6, 55.7, 55.7, 62.1, 70.3, 73.7, 75.5, 80.0, 84.5, 86.9, 113.5, 113.5, 117.4, 124.6, 127.1, 128.2, 129.1, 130.5, 136.8, 137.5, 137.8, 145.9, 150.3, 151.5, 151.6, 157.3, 158.2, 158.3. ESI-mass m/z calcd for C₄₃H₆₀N₅O₇Si₂ 814.4031; observed [M + H] 814.4508.

4.1.5. Typical procedure for the synthesis of nucleoside 5'-[ethyl *N*-(*N*-trityl-L-prolyl)phosphoramidate] derivatives **8a–g**.

4.1.5.1. 2',3'-*O*-Di-*tert*-butyldimethylsilyl-adenosine 5'-[ethyl *N*-(*N*-trityl-L-prolyl)phosphoramidate] (8a**).** A mixture of **6** (443 mg, 0.86 mmol) and **7a** (212 mg, 0.43 mmol) was coevaporated four times with dry acetonitrile and finally dissolved in dry acetonitrile (5 mL). To the mixture was added MMT (125 mg, 1.08 mmol), and the solution was stirred under argon atmosphere at room temperature for 1 h and then a 6 M solution of *tert*-butyl hydroperoxide in decane (717 μ L, 4.3 mmol) was added. After being stirred at room temperature for an additional 30 min, the mixture was diluted with CHCl₃. The CHCl₃ solution was washed with 5% NaHCO₃, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with hexane–AcOEt–pyridine, (100:0:1–99:1:1, v/v/v) to give a diastereomeric mixture of **8a** (244 mg, 60%): ¹H NMR (270 MHz, CDCl₃) δ –0.30 (3H, 2s, CH₃ of TBDMS), –0.13 (3H, 2s, CH₃ of TBDMS), –0.01 (6H, 2s), 0.68 (9H, 2s), 0.80 (9H, s), 0.81–1.51 (7H, m, $J_{POCH_2CH_3} = 7.9$ Hz), 2.90 (1H, m), 3.20 (1H, m), 3.90 (1H, m), 4.18–4.53 (6H, m), 4.70 (1H, m), 5.93 (1H, 2d, $J_{1',2'} = 4.9$ Hz), 6.70 (2H, br s), 6.99–7.08 (9H, m), 7.33–7.35 (6H, m), 8.13 (1H, 2s), 8.40 (1H, 2s); ¹³C NMR (CDCl₃) δ –5.2, –5.1, –4.91, –4.86, –4.8,

–4.6, –4.5, 16.0, 16.05, 16.10, 16.2, 17.65, 17.70, 17.8, 24.1, 25.5, 25.6, 25.7, 31.5, 50.4, 64.0, 64.1, 65.3, 65.4, 66.0, 66.1, 71.78, 71.80, 74.74, 74.75, 77.2, 77.9, 78.0, 82.81, 82.83, 83.0, 88.17, 88.18, 119.5, 119.6, 126.2, 126.3, 127.4, 127.6, 128.3, 128.8, 139.4, 143.75, 143.78, 149.3, 152.58, 152.60, 155.6, 177.28, 177.34; ³¹P NMR (CDCl₃) δ –1.31, –1.46. ESI-mass m/z calcd for C₄₈H₆₉N₇O₇PSi₂ 942.4535; observed [M + H] 942.4823.

4.1.5.2. 3'-*O*-*tert*-Butyldimethylsilyldeoxyadenosine 5'-[ethyl *N*-(*N*-trityl-L-prolyl)phosphoramidate] (8b**).** In a manner similar (see Table 1) to that described for the synthesis of **8a**, this compound was synthesized in 58% yield: ¹H NMR (270 MHz, CDCl₃) δ 0.08 (3H, s), 0.10 (3H, 2s), 0.64–0.90 (10H, m), 1.05–1.61 (6H, m, 3''-H, 4''-Hb, $J_{POCH_2CH_3} = 6.9$ Hz), 2.11–2.44 (1H, m), 2.69–2.82 (1H, m), 2.92–3.10 (1H, m), 3.20–3.36 (1H, m), 3.92–3.99 (1H, m), 4.16–4.32 (4H, m, $J_{POCH} = 10.6$ Hz), 4.42–4.44 (1H, m), 4.66–4.67 (1H, m, $J_{3',2'-Ha} = 2.6$ Hz), 6.44–6.56 (3H, m, $J_{1',2'-Ha} = 5.9$ Hz, $J_{1',2'-Hb} = 7.9$ Hz), 7.04–7.24 (9H, m), 7.41–7.44 (6H, m), 8.24 (1H, 2s), 8.28 (1H, 2s); ¹³C NMR (CDCl₃) δ –4.80, –4.76, –4.72, –4.67, 16.1, 16.2, 16.3, 17.9, 24.3, 25.68, 25.71, 31.7, 40.5, 41.0, 50.6, 50.7, 64.15, 64.22, 64.3, 65.5, 65.6, 66.8, 72.2, 72.3, 77.2, 78.2, 83.9, 84.1, 85.5, 85.6, 119.6, 119.7, 126.4, 126.5, 127.6, 127.7, 128.5, 129.0, 139.0, 139.1, 143.7, 143.8, 149.3, 149.3, 152.8, 155.5, 155.6, 177.4, 177.5; ³¹P NMR (CDCl₃) δ –1.61, –1.63. ESI-mass m/z calcd for C₄₂H₅₅N₇O₆PSi 812.3721; observed [M + H] 812.22703.

4.1.5.3. 3'-*O*-*tert*-Butyldimethylsilyl-8-oxoadenosine 5'-[ethyl *N*-(*N*-trityl-L-prolyl)phosphoramidate] (8c**).** In a manner similar (see Table 1) to that described for the synthesis of **8a**, this compound was synthesized in 43% yield: ¹H NMR (270 MHz, CDCl₃) δ 0.09 (3H, s), 0.10 (3H, s), 0.85–0.90 (10H, m), 1.06–1.58 (6H, m, $J_{POCH_2CH_3} = 7.3$ Hz), 2.12–2.20 (1H, m, $J_{2'-Ha,2'-Hb} = 5.6$ Hz), 2.85–2.97 (1H, m), 3.06–3.41 (2H, m), 3.89–3.97 (1H, m), 4.06–4.38 (5H, m, $J_{POCH} = 9.9$ Hz), 5.70 (2H, 2br s), 6.34 (1H, 2t, $J_{1',2'-Ha} = 6.6$ Hz, $J_{1',2'-Hb} = 6.9$ Hz), 7.09–7.30 (9H, m), 7.40–7.46 (6H, m), 8.02 (1H, 2s); ¹³C NMR (CDCl₃) δ –4.74, –4.72, –4.65, 16.1, 16.19, 16.22, 16.3, 18.0, 24.3, 24.4, 25.8, 25.9, 31.65, 31.68, 36.7, 36.8, 50.6, 64.6, 64.7, 65.3, 65.5, 67.25, 67.32, 72.4, 72.6, 77.2, 78.1, 81.5, 84.8, 85.0, 103.9, 126.4, 126.7, 127.6, 127.7, 128.5, 129.0, 143.7, 143.9, 144.0, 146.5, 146.6, 147.0, 147.1, 151.0, 152.1, 177.90, 177.94, 178.0, 178.1; ³¹P NMR (CDCl₃) δ –1.41, –1.50. ESI-mass m/z calcd for C₄₂H₅₅N₇O₇PSi 828.3670; observed [M + H] 828.3648.

4.1.5.4. 6-*N*-Acetyl-2',3'-*O*-di-*tert*-butyldimethylsilyl-7,8-dihydro-8-oxoadenosine 5'-[ethyl *N*-(*N*-trityl-L-prolyl)phosphoramidate] (8d**).** In a manner similar (see Table 1) to that described for the synthesis of **8a**, this compound was synthesized in 55% yield. Chromatography was performed by use of hexane–AcOEt (99.5:0.5–98.5:1.5, v/v): ¹H NMR (270 MHz, CDCl₃) δ –0.18 (3H, 2s), –0.03 (3H, 2s), 0.10–0.12 (6H, 4s), 0.78–0.91 (18H, m, 4''-Ha), 1.09–1.39 (5H, m, $J_{POCH_2CH_3} = 6.9$ Hz), 1.61 (1H, m), 2.19 (3H, s), 2.90–3.10 (1H, m),

3.22–3.34 (1H, m), 3.88–3.92 (1H, m), 4.21–4.65 (6H, m, $J_{\text{POCH}} = 0.2\text{ Hz}$), 5.06–5.12 (1H, m, 2'-H), 6.00 (1H, 2d, $J_{1',2'} = 4.9\text{ Hz}$), 7.08–7.27 (9H, m), 7.39–7.44 (6H, m), 8.19 (1H, 2s), 8.75 (1H, 2br s), 9.49 (1H, 2br s); ^{13}C NMR (CDCl_3) δ -4.81, -4.78, -4.7, -4.6, -4.5, -4.4, -4.3, 15.3, 16.18, 16.23, 16.29, 16.34, 17.92, 17.93, 18.07, 18.09, 23.0, 23.8, 24.25, 24.33, 25.71, 25.73, 25.9, 31.6, 31.7, 50.58, 50.60, 50.7, 52.0, 59.3, 64.35, 64.40, 64.43, 64.48, 65.46, 65.51, 65.6, 66.9, 66.95, 66.96, 67.00, 71.6, 71.9, 72.3, 72.4, 77.2, 78.1, 78.2, 81.9, 82.4, 82.5, 86.3, 86.4, 108.56, 108.62, 126.5, 126.3, 126.6, 126.7, 127.0, 127.5, 127.6, 127.70, 127.74, 127.8, 128.4, 128.5, 129.0, 137.7, 143.7, 144.0, 144.3, 146.7, 150.11, 150.13, 150.2, 150.7, 150.9, 151.0, 170.0, 170.1, 177.4, 177.5; ^{31}P NMR (CDCl_3) δ -1.79, -1.99; ESI-mass m/z calcd for $\text{C}_{50}\text{H}_{71}\text{N}_7\text{O}_9\text{PSi}_2$ 1000.4589; observed $[\text{M} + \text{H}]$ 1000.4662.

4.1.5.5. 2',3'-O-Di-*tert*-butyldimethylsilyluridine 5'-[ethyl *N*-(*N*-trityl-L-prolyl)phosphoroamidate] (8e). In a manner similar (see Table 1) to that described for the synthesis of **8a**, this compound was synthesized in 89% yield. Chromatography was performed by use of hexane–AcOEt (60:40, v/v): ^1H NMR (270 MHz, CDCl_3) δ 0.06–0.13 (12H, 6s), 0.87–0.92 (19H, m), 1.13–1.25 (1H, m), 1.36–1.45 (4H, m), 1.62 (1H, m, 3''-Hb), 2.96–3.09 (1H, m), 3.24–3.41 (1H, m), 3.88–3.97 (1H, m), 4.12–4.47 (7H, m), 5.74 (1H, 2d, 5-H, $J_{5,6} = 8.2\text{ Hz}$), 5.93 (1H, d, $J_{1',2'} = 4.6\text{ Hz}$), 6.75 (1H, br s), 7.12–7.27 (9H, m), 7.45–7.49 (6H, m), 7.86 (1H, 2d), 10.32 (1H, 2br s); ^{13}C NMR (CDCl_3) δ -4.9, -4.82, -4.77, -4.74, -4.66, -4.40, -4.35, 16.1, 16.20, 16.21, 16.3, 17.8, 17.87, 17.90, 17.93, 24.1, 24.2, 24.3, 25.6, 25.70, 25.73, 34.1, 50.3, 50.6, 63.9, 64.0, 64.06, 64.14, 64.9, 65.4, 65.45, 65.51, 65.57, 65.64, 65.7, 71.0, 74.9, 75.0, 77.2, 78.0, 78.11, 78.14, 82.4, 82.47, 82.51, 88.3, 88.4, 102.3, 102.4, 126.2, 126.4, 126.5, 127.5, 127.7, 128.9, 143.0, 143.8, 144.4, 150.4, 150.5, 163.5, 163.6, 177.16, 177.23, 177.25, 177.32; ^{31}P NMR (CDCl_3) δ -0.89, -1.14; ESI-mass m/z calcd for $\text{C}_{47}\text{H}_{68}\text{N}_4\text{O}_9\text{PSi}_2$ 919.4263; observed $[\text{M} + \text{H}]$ 919.4391.

4.1.5.6. 2',3'-O-Di-*tert*-butyldimethylsilyl-4-*N*-(4,4'-dimethoxytrityl)cytidine 5'-[ethyl *N*-(*N*-trityl-L-prolyl)phosphoroamidate] (8f). In a manner similar (see Table 1) to that described for the synthesis of **8a**, this compound was synthesized in 91% yield. Chromatography was performed by use of hexane– CHCl_3 (20:80–0:100, v/v): ^1H NMR (270 MHz, CDCl_3) δ 0.00–0.78 (12H, m), 0.84–1.54 (25H, m), 2.97–3.10 (1H, m, 5''-Ha), 3.19–3.29 (1H, m), 3.70 (6H, 2s), 3.74 (1H, m), 3.86–4.40 (7H, m), 5.09 (1H, 2d, 1'-H, $J_{1',2'} = 6.5\text{ Hz}$), 5.87 (1H, d, 5-H, $J_{5,6} = 4.3\text{ Hz}$), 6.74 (4H, d, $J_{\text{ortho,meta}} = 8.9\text{ Hz}$), 7.07–7.24 (18H, m), 7.40–7.56 (7H, m); ^{13}C NMR (CDCl_3) δ -5.0, -4.91, -4.88, -4.7, -4.5, -4.4, -4.3, 15.3, 16.1, 16.2, 16.3, 17.9, 17.95, 17.98, 24.1, 24.20, 24.23, 25.7, 25.77, 25.80, 25.9, 31.5, 31.6, 34.2, 50.3, 50.6, 55.0, 55.1, 59.2, 63.96, 64.00, 64.0, 64.1, 64.9, 65.4, 65.5, 65.6, 66.1, 66.07, 66.09, 66.12, 66.2, 69.9, 70.8, 71.1, 75.0, 75.1, 77.2, 78.1, 78.2, 81.7, 89.67, 89.69, 94.7, 94.8, 113.3, 126.2, 126.5, 126.9, 127.1, 127.4, 127.6, 127.7, 128.0, 128.26, 128.33, 129.0, 129.6, 136.0, 136.1, 141.0, 141.3,

143.1, 143.8, 144.2, 144.4, 146.7, 158.25, 158.28, 164.95, 165.00, 176.75, 176.81, 176.95, 177.00; ^{31}P NMR (CDCl_3) δ -1.62, -1.93; ESI-mass m/z calcd for $\text{C}_{68}\text{H}_{87}\text{N}_5\text{O}_{10}\text{PSi}_2$ 1220.5729; observed $[\text{M} + \text{H}]$ 1220.5531.

4.1.5.7. 2',3'-O-Di-*tert*-butyldimethylsilyl-2-*N*-(4,4'-dimethoxytrityl)guanosine 5'-[ethyl *N*-(*N*-trityl-L-prolyl)phosphoroamidate] (8g). In a manner similar (see Table 1) to that described for the synthesis of **8a**, this compound was synthesized in 72% yield. Chromatography was performed by use of hexane–MeOH (99.5:0.5–99:1, v/v): ^1H NMR (270 MHz, CDCl_3) δ -0.27 (3H, 2s), -0.08 (3H, 2s), 0.08 (3H, 2s), 0.11 (3H, 2s), 0.75–0.80 (9H, m), 0.81–1.09 (10H, m), 1.20–1.38 (5H, m), 1.55–1.61 (1H, m), 2.94–3.04 (1H, m), 3.27–3.29 (1H, m), 3.68 (6H, s), 3.87–3.94 (1H, m), 4.11–4.26 (6H, m), 4.38–4.40 (1H, m), 4.56–4.60 (1H, m), 5.61 (1H, 2d, $J_{1',2'} = 6.5\text{ Hz}$), 6.75 (4H, d, $J_{\text{ortho,meta}} = 7.9\text{ Hz}$), 7.04–7.30 (18H, m), 7.40–7.44 (6H, m), 7.70 (1H, s), 8.66 (1H, s), 8.88 (1H, 2br s); ^{13}C NMR (CDCl_3) δ -4.5, -4.3, -4.0, -3.9, -3.8, -3.74, -3.73, 16.85, 16.92, 16.96, 17.02, 18.56, 18.61, 18.67, 18.68, 18.70, 18.74, 24.97, 25.00, 26.4, 26.45, 26.49, 32.2, 35.0, 51.3, 51.4, 55.8, 55.9, 64.8, 64.87, 64.92, 65.0, 66.1, 66.2, 66.25, 66.31, 67.47, 67.51, 67.56, 67.58, 70.8, 70.9, 73.1, 73.3, 75.3, 78.0, 78.85, 78.88, 84.09, 84.10, 84.2, 84.3, 84.4, 86.9, 114.1, 114.8, 118.35, 118.40, 127.1, 127.2, 127.4, 127.8, 128.19, 128.24, 128.3, 128.4, 128.47, 128.76, 128.84, 129.1, 129.2, 129.7, 130.3, 136.15, 136.22, 136.27, 136.32, 136.7, 136.9, 143.9, 144.4, 144.6, 144.8, 144.9, 151.5, 151.6, 151.9, 152.0, 157.3, 159.0, 159.6, 177.87, 177.93, 178.1, 178.2; ^{31}P NMR (CDCl_3) δ -1.61, -1.83; ESI-mass m/z calcd for $\text{C}_{69}\text{H}_{87}\text{N}_7\text{O}_{10}\text{PSi}_2$ 1260.5791; observed $[\text{M} + \text{H}]$ 1260.5618.

4.1.6. Adenosine 5'-[ethyl *N*-(L-prolyl)phosphoroamidate] (A-phosmidosine) trifluoroacetic acid salt (9a). Compound **8a** (244 mg, 0.26 mmol) was dissolved in 80% formic acid (2.6 mL). After being stirred at room temperature for 42 h, the mixture was diluted with distilled water. The aqueous solution was washed three times with CHCl_3 , evaporated under reduced pressure, and coevaporated with distilled water under reduced pressure. The residue was chromatographed on a column of C_{18} by using medium pressure chromatography with solvent system II. The fractions containing **9a** were collected and lyophilized. The residue was rechromatographed on a column of C_{18} with water–acetonitrile (95:5, v/v) followed by lyophilization from its aqueous solution to give **9a** as the TFA salt (29 mg, 19%): ^1H NMR (270 MHz, D_2O) δ 1.13 (3H, t, $J_{\text{POCH}_2\text{CH}_3} = 6.9\text{ Hz}$), 1.81–1.91 (3H, m), 2.32 (1H, m), 3.24 (2H, m), 3.97–4.07 (2H, m), 4.29–4.35 (5H, m), 4.65 (1H, m), 6.01 (1H, d, $J_{1',2'} = 2.0\text{ Hz}$), 8.28 (1H, s), 8.33 (1H, s); ^{13}C NMR (D_2O) δ 17.88, 17.90, 17.97, 17.99, 26.1, 31.98, 32.02, 49.1, 63.0, 63.2, 68.5, 68.56, 68.60, 68.65, 69.2, 69.3, 69.4, 72.2, 76.5, 85.0, 85.07, 85.14, 85.2, 91.1, 91.2, 112.4, 116.6, 120.9, 121.2, 121.3, 125.2, 144.87, 144.91, 147.0, 150.7, 152.3, 164.5, 165.0, 165.5, 166.0, 174.0, 174.1; ^{31}P NMR (D_2O) δ -1.15, -1.21. ESI-mass m/z calcd for $\text{C}_{17}\text{H}_{27}\text{N}_7\text{O}_7\text{P}$ 472.1710; observed $[\text{M} + \text{H}]$ 472.1729.

4.1.7. Deoxyadenosine 5'-[ethyl *N*-(*L*-prolyl)phosphoramidate] (dA-phosmidosine) (9b). Compound **8b** (118 mg, 0.15 mmol) was dissolved in THF (1.5 mL), and Bu₄NF·H₂O (152 mg, 0.58 mmol) was added. After being stirred at room temperature for 6 h, the mixture was diluted with CHCl₃. The CHCl₃ solution was washed three times with 5% NaHCO₃, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was dissolved in a 1% solution of TFA in water–acetonitrile (1:1, v/v, 1.5 mL). After being stirred at room temperature for 15 min, the mixture was diluted with distilled water. The aqueous solution was washed three times with CHCl₃, evaporated under reduced pressure, and coevaporated with distilled water under reduced pressure. The residue was chromatographed on a column of C₁₈ by using medium pressure chromatography with solvent system I. The fractions containing **9b** were collected and lyophilized. The residue was rechromatographed on a column of C₁₈ with water–acetonitrile (90:10, v/v) followed by lyophilization from its aqueous solution to give **9b** as the free form (48 mg, 72%): ¹H NMR (270 MHz, D₂O) δ 1.09 (3H, 2t, *J*_{POCH₂CH₃} = 6.9 Hz), 1.81–2.02 (3H, m), 2.25–2.38 (1H, m), 2.57–2.66 (1H, m, *J*_{2'-Ha,2'-Hb} = 6.6 Hz), 2.77–2.88 (1H, m), 3.24–3.41 (2H, m), 3.73–3.84 (2H, m, *J*_{POCH} = 10.6 Hz), 4.07–4.16 (3H, m), 4.24–4.25 (1H, m), 4.69–4.74 (1H, m, *J*_{1',2'-Hb} = 4.3 Hz), 6.37 (1H, dd, *J*_{1',2'-Ha} = 6.3 Hz, *J*_{1',2'-Hb} = 6.6 Hz), 8.09 (1H, s), 8.27 (1H, 2s); ¹³C NMR (D₂O) δ 17.9, 18.0, 26.4, 32.4, 41.3, 41.4, 48.8, 64.7, 65.0, 65.4, 65.47, 65.50, 65.58, 67.56, 67.64, 67.7, 67.8, 73.4, 86.28, 86.34, 87.8, 87.88, 87.91, 120.9, 141.9, 150.79, 150.82, 154.9, 157.6, 178.5, 178.6; ³¹P NMR (D₂O) δ 10.57; ESI-mass *m/z* calcd for C₁₇H₂₇N₇O₆P 456.1761; observed [M + H] 456.1582.

4.1.8. 7,8-Dihydro-8-oxodeoxyadenosine 5'-[ethyl *N*-(*L*-prolyl)phosphoramidate] (8-oxo-dA-phosmidosine) (9c). This compound was synthesized in 58% yield as the free form in a manner similar to that described for the synthesis of **9b**: ¹H NMR (270 MHz, D₂O) δ 1.10–1.16 (3H, 2t, *J*_{POCH₂CH₃} = 6.9 Hz), 1.90–2.07 (3H, m), 2.30–2.40 (2H, m, 3'-Hb), 3.15–3.39 (3H, m), 3.81–3.95 (2H, m, *J*_{POCH} = 9.9 Hz), 4.11 (4H, m), 4.71 (1H, m, 3'-H), 6.21 (1H, t, *J*_{1',2'-Ha} = *J*_{1',2'-Hb} = 6.6 Hz), 7.98 (1H, s); ¹³C NMR (CDCl₃) δ 17.9, 18.0, 26.4, 32.4, 37.6, 48.8, 64.7, 65.1, 65.3, 65.4, 67.96, 67.98, 68.03, 68.1, 73.4, 73.5, 84.05, 84.12, 86.8, 87.0, 106.4, 148.8, 149.5, 153.3, 155.1, 178.7, 178.8; ³¹P NMR (CDCl₃) δ 10.79, 10.87. ESI-mass *m/z* calcd for C₁₇H₂₇N₇O₇P 472.1710; observed [M + H] 472.5253.

4.1.9. 6-*N*-Acetyl-7,8-dihydro-8-oxodeoxyadenosine 5'-[ethyl *N*-(*L*-prolyl)phosphoramidate] (*N*⁶-Ac-dA-phosmidosine) (9d). This compound was synthesized in 29% yield as the free form in a manner similar to that described for the synthesis of **9b**: ¹H NMR (270 MHz, D₂O) δ 1.13 (3H, t, *J*_{POCH₂CH₃} = 6.9 Hz), 1.96–2.07 (3H, m), 2.27–2.32 (4H, m), 3.30–3.44 (2H, m), 3.83–3.93 (2H, m), 4.09–4.22 (4H, m), 4.65–4.69 (1H, m), 5.17–5.20 (1H, m), 5.95 (1H, d, *J*_{1',2'} = 4.6 Hz), 8.40 (1H, s); ¹³C NMR (D₂O) δ 17.9, 18.0, 32.4, 48.8, 64.7, 65.1, 65.4, 65.5, 67.6, 67.7, 72.3, 73.2, 73.3, 84.5, 84.7, 88.8, 113.5, 140.3, 152.8, 153.0, 154.8, 175.2, 178.6,

178.7. ³¹P NMR (D₂O) δ 10.70; ESI-mass *m/z* calcd for C₁₉H₂₉N₇O₉P 530.1764; observed [M + H] 530.1832.

4.1.10. Uridine 5'-[ethyl *N*-(*L*-prolyl)phosphoramidate] (U-phosmidosine) (9e). This compound was synthesized in 91% yield as the free form in a manner similar to that described for the synthesis of **9b**: ¹H NMR (270 MHz, D₂O) δ 1.33–1.38 (3H, 2t, *J*_{POCH₂CH₃} = 6.9 Hz), 2.01–2.18 (3H, m), 2.43–2.59 (1H, m), 3.34–3.51 (2H, m), 4.22–4.55 (8H, m, *J*_{POCH} = 11.2 Hz), 5.88–5.92 (2H, 2d, 1'-H, 5-H, *J*_{1',2'} = 5.3 Hz), 7.74 (1H, 2d, *J*_{6,5} = 8.2 Hz); ¹³C NMR (D₂O) δ 18.1, 18.2, 26.4, 32.5, 48.9, 64.8, 65.2, 65.65, 65.68, 65.72, 67.17, 67.20, 67.22, 67.24, 67.27, 67.29, 67.3, 71.9, 70.0, 76.2, 76.3, 85.0, 85.1, 85.2, 85.3, 91.6, 104.8, 144.0, 144.1, 154.1, 168.6, 178.85, 178.88, 178.93, 179.0; ³¹P NMR (D₂O) δ 11.07; ESI-mass *m/z* calcd for C₁₆H₂₆N₄O₉P 449.1437; observed [M + H] 449.1453.

4.1.11. Cytidine 5'-[ethyl *N*-(*L*-prolyl)phosphoramidate] (C-phosmidosine) TFA salt (9f). Compound **8f** (223 mg, 0.18 mmol) was dissolved in THF (1.8 mL), and Bu₄NF·H₂O (383 mg, 1.46 mmol) was added. After being stirred at room temperature for 1 h, the mixture was diluted with CHCl₃. The CHCl₃ solution was washed three times with 5% NaHCO₃, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was dissolved in a 4% solution of TFA in water–acetonitrile (1:1, v/v, 1.8 mL). After the mixture was stirred at room temperature for 3 h, trifluoroacetic acid (73 μL, 0.99 mmol) was added. After being stirred at room temperature for an additional 12 h, the mixture was diluted with distilled water. The aqueous solution was washed 3 times with AcOEt, evaporated under reduced pressure, and coevaporated with distilled water under reduced pressure. The residue was chromatographed on a column of C₁₈ by using medium pressure chromatography with solvent system I. The fractions containing **9e** were collected and lyophilized. The residue was rechromatographed on a column of C₁₈ with water–acetonitrile (95:5, v/v) followed by lyophilization from its aqueous solution to give **9f** as the TFA form (62 mg, 60%): ¹H NMR (270 MHz, D₂O) δ 1.32 (3H, t, *J*_{POCH₂CH₃} = 6.9 Hz), 1.96–2.13 (3H, m), 2.47–2.52 (1H, m), 3.39–3.41 (2H, m), 4.18–4.49 (8H, m), 5.84–5.85 (1H, m), 6.11–6.13 (1H, m), 7.79–7.83 (1H, m); ¹³C NMR (D₂O) δ 17.9, 18.01, 18.03, 26.1, 31.96, 31.99, 49.0, 49.2, 63.0, 63.2, 68.5, 68.56, 68.6, 69.1, 69.16, 69.23, 71.26, 71.33, 76.2, 84.0, 84.1, 93.1, 98.1, 112.3, 116.6, 120.9, 125.19, 145.1, 155.5, 155.6, 164.5, 165.0, 165.2, 165.3, 165.5, 166.1, 174.09, 174.12; ³¹P NMR (D₂O) δ -0.90, -0.95; ESI-mass *m/z* calcd for C₁₆H₂₇N₅O₈P 448.1597; observed [M + H] 448.1583.

4.1.12. Guanosine 5'-[ethyl *N*-(*L*-prolyl)phosphoramidate] (G-phosmidosine) (9g). This compound was synthesized in 69% yield as the free form in a manner similar to that described for the synthesis of **9b**: ¹H NMR (270 MHz, D₂O) δ 1.16 (3H, t, *J*_{POCH₂CH₃} = 7.3 Hz), 2.85–2.06 (3H, m), 2.26–2.39 (1H, m), 3.24–3.43 (2H, m), 3.81–3.97 (2H, m, *J*_{POCH} = 11.5 Hz), 4.09–4.32 (4H, m), 4.45–4.50 (1H, m), 4.68 (1H, m, *J*_{2',3'} = 4.9 Hz), 5.83 (1H, d, *J*_{1',2'} = 4.6 Hz), 7.92 (1H, d); ¹³C NMR

(D₂O) δ 17.9, 17.95, 18.03, 18.1, 26.4, 32.4, 48.8, 64.7, 65.1, 65.5, 65.6, 65.7, 67.1, 67.2, 67.3, 67.4, 72.55, 72.59, 76.25, 76.30, 85.4, 85.5, 89.75, 89.78, 118.40, 118.43, 139.4, 139.5, 153.77, 153.80, 156.07, 156.09, 160.9, 178.6, 178.67, 178.70, 178.8; ³¹P NMR (D₂O) δ 10.63, 10.73. ESI-mass m/z calcd for C₁₇H₂₇N₇O₈P 488.1659; observed [M + H] 488.1658.

4.1.13. 7,8-Dihydro-8-oxodeoxyadenosine. 8-Bromodeoxyadenosine²¹ (6.6 g, 20 mmol) was dissolved in a mixture of acetic acid–acetic anhydride (1:1, v/v, 400 mL), and sodium acetate (30 g, 366 mmol) was added. After being stirred at 120°C for 30 min, the mixture was diluted with CHCl₃. The CHCl₃ solution was washed five times with distilled water, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was dissolved in AcOEt. The AcOEt solution was washed 5% NaHCO₃, filtered, and evaporated under reduced pressure. The residue was dissolved in ethanol (86 mL), and NaOH (1.7 g, 43 mmol) was added. After being stirred at room temperature for 3 h, the mixture was stirred at 60°C for an additional 1 h. The mixture was neutralized by addition of 4 M HCl (10 mL) and 5% NaHCO₃. The precipitates were removed by filtration and washed three times with distilled water. The filtrate and washings were collected and evaporated under reduced pressure. The residue was chromatographed on a column of C₁₈ with water–acetonitrile (100:0–98:2, v/v) to give the title compound as ochreous solids (1.6 g, 28%): ¹H NMR (270 MHz, DMSO-*d*₆) δ 1.92–2.00 (1H, m, $J_{2'-Ha,2'-Hb}$ = 4.6 Hz), 2.89–2.99 (1H, m), 3.41–3.47 (1H, m), 3.57–3.63 (1H, m), 3.79–3.80 (1H, m), 4.36–4.38 (1H, m, $J_{3',2'-Hb}$ = 5.3 Hz), 6.13 (1H, dd, $J_{1',2'-Ha}$ = 6.3 Hz, $J_{1',2'-Hb}$ = 8.2 Hz), 7.19 (2H, br s), 7.91 (1H, s); ¹³C NMR (DMSO-*d*₆) δ 36.5, 62.5, 71.5, 81.6, 87.5, 104.7, 146.1, 147.6, 149.7, 152.1. ESI-mass m/z calcd for C₁₀H₁₄N₅O₄ 268.1046; observed [M + H] 268.1027.

Acknowledgements

This work was supported by Grant-in-Aid for Scientific Research on Priority Areas (C) ‘Genome Science’ from the Ministry of Education, Culture, Sports, Science and Technology of Japan. This work was also supported

by CREST of JST (Japan Science and Technology Corporation) and COE21 project.

References and notes

1. Uramoto, M.; Kim, C. J.; Shin-ya, K.; Kusakabe, H.; Isono, K.; Phillips, D. R.; McCloskey, J. A. *J. Antibiot.* **1991**, *44*, 375.
2. Phillips, D. R.; Uramoto, M.; Isono, K.; McCloskey, J. A. *J. Org. Chem.* **1993**, *58*, 854.
3. Matsuura, N.; Onose, R.; Osada, H. *J. Antibiot.* **1996**, *49*, 361.
4. Kakeya, H.; Onose, R.; Phillip, C.-C. L.; Onozawa, C.; Matsumura, F.; Osada, H. *Cancer Res.* **1998**, *58*, 704.
5. Moriguchi, T.; Asai, N.; Wada, T.; Seio, K.; Sasaki, T.; Sekine, M. *Tetrahedron Lett.* **2000**, *41*, 5881.
6. Moriguchi, T.; Asai, N.; Okada, K.; Seio, K.; Sasaki, T.; Sekine, M. *J. Org. Chem.* **2002**, *67*, 3290.
7. Sekine, M.; Okada, K.; Seio, K.; Kakeya, H.; Osada, H.; Sasaki, T. *J. Org. Chem.* **2004**, *69*, 314.
8. Moriguchi, T.; Yanagi, T.; Wada, T.; Sekine, M. *Tetrahedron Lett.* **1998**, *39*, 3725.
9. Moriguchi, T.; Yanagi, T.; Kunimori, M.; Wada, T.; Sekine, M. *J. Org. Chem.* **2000**, *65*, 8229.
10. Filippov, D.; Timmers, C. M.; van der Marel, G. A.; van Boom, J. H. *Nucleos. Nucleot.* **1997**, *16*, 1403.
11. Filippov, D.; Timmers, C. M.; Roerdink, A. R.; van der Marel, G. A.; van Boom, J. H. *Tetrahedron Lett.* **1998**, *39*, 4891.
12. Jaeger, A.; Engels, J. *Tetrahedron Lett.* **1984**, *25*, 1437.
13. Ogilvie, K. K.; Beaucage, S. L.; Schiffman, A. L.; Theriault, N. Y.; Sadana, K. L. *Can. J. Chem.* **1978**, *56*, 2768.
14. Zhang, W.; Robins, M. J. *Tetrahedron Lett.* **1992**, *33*, 1177.
15. Carmichael, DeGraff, W. G.; Gazar, A. F.; Minna, J. D.; Mitchell, J. B. *Cancer Res.* **1987**, *47*, 936.
16. Yu, X. Y.; Hill, J. M.; Yu, G.; Wang, W.; Kluge, A.; Wendler, P.; Gallant, P. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 375–380, and references cited therein.
17. Heacock, D.; Forsyth, C. J.; Shiba, K.; Musier-Forsyth, K. *Bioorg. Chem.* **1996**, *24*, 273.
18. Castro-Pichel, J.; Garcia-Lopez, M. T.; de Las Heras, F. G. *Tetrahedron* **1987**, *43*, 383.
19. Isono, K.; Uramoto, M.; Kusakabe, H.; Miyata, N.; Koyama, T.; Ubukata, M.; Sethi, S. K.; McCloskey, J. A. *J. Antibiot.* **1984**, *37*, 670.
20. Davison, E. C.; Johnsson, K. *Nucleos. Nucleot.* **1993**, *12*, 237.
21. Catalanotti, B.; Galeone, A.; Gomez-Paloma, L.; Mayol, L.; Pepe, A. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2005.